Zymeworks (NASDAQ:ZYME) Downgraded by Wall Street Zen to Buy

Wall Street Zen downgraded shares of Zymeworks (NASDAQ:ZYME) from a strong-buy rating to a buy rating in a research note issued to investors on Sunday.

Several other research firms have also recently commented on ZYME. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a report on Wednesday, October 8th. B. Riley raised shares of Zymeworks to a “strong-buy” rating in a research report on Thursday, October 9th. Finally, HC Wainwright upgraded shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Zymeworks currently has an average rating of “Buy”.

Zymeworks Trading Down 0.8%

Shares of NASDAQ ZYME opened at $18.40 on Friday. The stock has a market cap of $1.38 billion, a P/E ratio of -18.97 and a beta of 1.51. The business’s 50-day moving average is $15.76. Zymeworks has a 1-year low of $9.03 and a 1-year high of $19.50.

Zymeworks (NASDAQ:ZYME) last announced its quarterly earnings data on Tuesday, November 8th. The company reported ($1.14) earnings per share (EPS) for the quarter. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%. The company had revenue of $4.40 million during the quarter.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.